Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tremelimumab + durvalumab
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Tremelimumab and durvalumab is a combination of two monoclonal antibodies used as an immunotherapy for certain cancers. Tremelimumab is a fully human IgG2 monoclonal antibody that targets cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), acting as an immune checkpoint inhibitor to enhance T cell-mediated anti-tumor activity. Durvalumab is a human IgG1 monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80, thereby promoting immune responses against tumor cells. The combination has been approved for the treatment of unresectable hepatocellular carcinoma and metastatic non-small cell lung cancer without EGFR or ALK mutations. Both drugs are developed by AstraZeneca[3][5][6][8].
- Brand names
- Imjudo + Imfinzi
- Other names
- tremelimumab-actl
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on tremelimumab + durvalumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tremelimumab + durvalumab.